Skip to main content
Canna~Fangled Abstracts

A Semi-Naturalistic, Open-Label Trial Examining the Effect of Prescribed Medical Cannabis on Neurocognitive Performance

By November 9, 2023November 15th, 2023No Comments

. 2023 Nov 9.

doi: 10.1007/s40263-023-01046-z.

Online ahead of print.
Thomas R Arkell 1, Brooke Manning 1, Luke A Downey 1 2, Amie C Hayley 3 4
Affiliations 

Abstract

Background and objectives: Medical cannabis use is increasing in Australia and other jurisdictions, yet little is known about the effects of medical cannabis on cognitive function. Findings from studies of non-medical (‘recreational’) cannabis may not be applicable to patients using prescribed medical cannabis to manage a health condition.

Methods: In this semi-naturalistic, open-label trial, patients with various health conditions attended a single laboratory session in which they self-administered a standard dose of prescribed medical cannabis as per instructions on the pharmacy label. We assessed cognitive performance using the Cambridge Neuropsychological Test Automated Battery (CANTAB) and Druid application (app) prior to and following (CANTAB: + 3 h; Druid: + 3 and 5.5 h) medical cannabis self-administration. We also assessed subjective drug effects prior to and following (1, 2 and 4 h) medical cannabis self-administration using a range of 0-10 cm visual analogue scales (‘stoned’, ‘sedated’, ‘relaxed’, ‘comfortable’, ‘anxious’ and ‘confident’). Data were analyzed using linear fixed-effect models.

Results: Participants (N = 40; 22 females) were prescribed a range of products including orally administered oils (n = 23) and flower for vaporization (n = 17). Participants had a mean (standard deviation [SD]) age of 41.38 (12.66) years and had been using medical cannabis for a mean (SD) of 10.18 (8.73) months. Chronic non-cancer pain was the most common indication for medical cannabis use (n = 20), followed by sleep disorder (n = 18) and anxiety (n = 11). The mean (SD) delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) dose administered by participants was 9.61 (8.52) mg/9.15 (10.11) mg among those using an oil, and 37.00 (24.53) mg/0.38 (1.58) mg among those who vaporized flower, respectively. Participants’ performance improved over time on the CANTAB Multitasking Test and Rapid Visual Information Processing test (both p-values <0.001). All other changes in cognitive performance measures over time were non-significant (p > 0.05). Vaporization of flower was associated with significantly stronger subjective feelings of ‘stoned’ and ‘sedated’ relative to oils (both p < 0.001).

Conclusions: These findings suggest that prescribed medical cannabis may have minimal acute impact on cognitive function among patients with chronic health conditions, although larger and controlled trials are needed.

PubMed Disclaimer

References

    1. Therapeutic Goods Administration. Medicinal Cannabis Special Access Scheme Category B data. Medicinal Cannabis 2023. https://www.tga.gov.au/medicinal-cannabis-special-access-scheme-category… . Accessed 24 May 2023
    1. Therapeutic Goods Administration. Medicinal cannabis: Access pathways and patient access data. Medicinal cannabis hub 2023. https://www.tga.gov.au/products/unapproved-therapeutic-goods/medicinal-c… . Accessed 24 May 2023
    1. Broyd SJ, van Hell HH, Beale C, Yucel M, Solowij N. Acute and chronic effects of cannabinoids on human cognition-a systematic review. Biol Psychiatry. 2016;79(7):557–67. https://doi.org/10.1016/j.biopsych.2015.12.002 . – DOI – PubMed
    1. Bridgeman MB, Abazia DT. Medicinal cannabis: history, pharmacology, and implications for the acute care setting. P T. 2017;42(3):180–8. – PubMed – PMC
    1. Moriarty O, McGuire BE, Finn DP. The effect of pain on cognitive function: a review of clinical and preclinical research. Prog Neurobiol. 2011;93(3):385–404. https://doi.org/10.1016/j.pneurobio.2011.01.002 . – DOI – PubMed

LinkOut – more resources

Leave a Reply